MX2020003462A - Metodos para la administracion de ciertos inhibidores del transportador vesicular de monoamina 2 (vmat2). - Google Patents
Metodos para la administracion de ciertos inhibidores del transportador vesicular de monoamina 2 (vmat2).Info
- Publication number
- MX2020003462A MX2020003462A MX2020003462A MX2020003462A MX2020003462A MX 2020003462 A MX2020003462 A MX 2020003462A MX 2020003462 A MX2020003462 A MX 2020003462A MX 2020003462 A MX2020003462 A MX 2020003462A MX 2020003462 A MX2020003462 A MX 2020003462A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- administration
- vmat2 inhibitors
- patient
- certain
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
- C07D455/06—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine containing benzo [a] quinolizine ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762451605P | 2017-01-27 | 2017-01-27 | |
| PCT/US2017/055907 WO2018140093A1 (en) | 2017-01-27 | 2017-10-10 | Methods for the administration of certain vmat2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020003462A true MX2020003462A (es) | 2020-08-03 |
Family
ID=62978647
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020003462A MX2020003462A (es) | 2017-01-27 | 2017-10-10 | Metodos para la administracion de ciertos inhibidores del transportador vesicular de monoamina 2 (vmat2). |
| MX2019008855A MX394417B (es) | 2017-01-27 | 2017-10-10 | Metodos para la administracion de ciertos inhibidores del transportador de monamina vesicular 2 (vmat2). |
| MX2019008854A MX394418B (es) | 2017-01-27 | 2017-10-10 | Metodos para la administracion de ciertos inhibidores del tranportador de monoamina vesicular 2 (vmat2). |
| MX2019008853A MX394415B (es) | 2017-01-27 | 2017-10-10 | Metodos para la administracion de ciertos inhibidores de proteina transportadora transportador de monoamina vesicular-2 (vmat2). |
| MX2019008868A MX393077B (es) | 2017-01-27 | 2017-10-10 | Métodos para la administración de ciertos inhibidores de proteína transportadora transportador de monoamina vesicular (vmat2). |
| MX2022007141A MX2022007141A (es) | 2017-01-27 | 2019-07-25 | Metodos para la administracion de ciertos inhibidores de proteina transportadora transportador de monoamina vesicular (vmat2). |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019008855A MX394417B (es) | 2017-01-27 | 2017-10-10 | Metodos para la administracion de ciertos inhibidores del transportador de monamina vesicular 2 (vmat2). |
| MX2019008854A MX394418B (es) | 2017-01-27 | 2017-10-10 | Metodos para la administracion de ciertos inhibidores del tranportador de monoamina vesicular 2 (vmat2). |
| MX2019008853A MX394415B (es) | 2017-01-27 | 2017-10-10 | Metodos para la administracion de ciertos inhibidores de proteina transportadora transportador de monoamina vesicular-2 (vmat2). |
| MX2019008868A MX393077B (es) | 2017-01-27 | 2017-10-10 | Métodos para la administración de ciertos inhibidores de proteína transportadora transportador de monoamina vesicular (vmat2). |
| MX2022007141A MX2022007141A (es) | 2017-01-27 | 2019-07-25 | Metodos para la administracion de ciertos inhibidores de proteina transportadora transportador de monoamina vesicular (vmat2). |
Country Status (12)
| Country | Link |
|---|---|
| US (9) | US20200093808A1 (enExample) |
| JP (16) | JP7107950B2 (enExample) |
| KR (14) | KR20230170136A (enExample) |
| CN (6) | CN110740731A (enExample) |
| AU (7) | AU2017395703B2 (enExample) |
| CA (5) | CA3051834C (enExample) |
| EA (5) | EA202090676A1 (enExample) |
| MX (6) | MX2020003462A (enExample) |
| MY (5) | MY202219A (enExample) |
| PH (6) | PH12022553251A1 (enExample) |
| SG (3) | SG11201906891RA (enExample) |
| WO (5) | WO2018140095A2 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX381258B (es) | 2015-10-30 | 2025-03-12 | Neurocrine Biosciences Inc | Sales de valbenazina y polimorfos de las mismas. |
| CN121045173A (zh) | 2015-12-23 | 2025-12-02 | 纽罗克里生物科学有限公司 | 制备3-异丁基-9,10-二甲氧基-六氢-1H-吡啶并[2,1-a]异喹啉-2-基2-氨基-3-甲基丁酸酯的盐的方法 |
| US20200093808A1 (en) | 2017-01-27 | 2020-03-26 | Neurocrine Biosciences, Inc. | Methods for the Administration of Certain VMAT2 Inhibitors |
| GB201705304D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705306D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705302D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705303D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| EP3684333B1 (en) | 2017-09-21 | 2025-03-05 | Neurocrine Biosciences, Inc. | High dosage valbenazine formulation and compositions, methods, and kits related thereto |
| KR20250070134A (ko) | 2017-10-10 | 2025-05-20 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| MY198713A (en) | 2017-10-10 | 2023-09-19 | Neurocrine Biosciences Inc | Methods for the administration of certain vmat2 inhibitors |
| JP7212958B2 (ja) | 2017-12-26 | 2023-01-26 | ▲蘇▼州科睿思制▲葯▼有限公司 | バルベナジントシル酸塩の結晶形及びその製造方法並びに用途 |
| MX2020011269A (es) | 2018-04-25 | 2020-12-11 | Shinkei Therapeutics Llc | Dispositivo de administración transdérmica de tetrabenazina. |
| GB201808464D0 (en) | 2018-05-23 | 2018-07-11 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compounds for use in treating huntington's disease |
| US20200345663A1 (en) * | 2018-06-10 | 2020-11-05 | Axsome Therapeutics, Inc. | Methods of modulating tetrabenazine metabolites plasma levels using bupropion |
| MX2021001017A (es) * | 2018-08-15 | 2021-04-19 | Neurocrine Biosciences Inc | Metodos para la administracion de ciertos inhibidores de transportador vesicular de monoamina de proteinas transportadoras-2 (vmat2). |
| JP2022531696A (ja) * | 2019-05-09 | 2022-07-08 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 特定のｖｍａｔ２阻害剤を投与するための方法 |
| TW202114676A (zh) * | 2019-08-14 | 2021-04-16 | 瑞士商Ｆ 賀夫曼 賀許公司 | 治療癌症之方法 |
| US10940141B1 (en) * | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
| TW202137986A (zh) * | 2019-12-20 | 2021-10-16 | 日商衛材R&D企管股份有限公司 | 治療失眠之方法 |
| IL309171A (en) | 2021-06-30 | 2024-02-01 | Neurocrine Biosciences Inc | Vulbanazine for use in the treatment of dyskinesia due to cerebral palsy |
| JP2024524324A (ja) | 2021-06-30 | 2024-07-05 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 統合失調症のアドオン処置において使用するためのバルベナジン |
| IL310584A (en) * | 2021-08-16 | 2024-04-01 | Foresee Pharmaceuticals Co Ltd | Depot polymer formulations for sustained release administration of VMAT2 inhibitors |
| CA3229341A1 (en) | 2021-08-20 | 2023-02-23 | Ryan TERRY-LORENZO | Methods of screening for vmat2 inhibitors |
| EP4398893A4 (en) * | 2021-09-10 | 2025-07-16 | ATAI Life Sciences AG | IBOGAINE COMBINATION THERAPY |
| WO2023076568A1 (en) * | 2021-10-29 | 2023-05-04 | Neurocrine Biosciences, Inc. | Valbenazine compositions |
| AU2023232134A1 (en) | 2022-03-07 | 2024-10-03 | Neurocrine Biosciences, Inc. | Valbenazine, a vmat2 inhibitor, as a free base a tosylate or ditosylate salt, for use in the treatment of chorea associated with huntington's disease |
| US20240156723A1 (en) * | 2022-11-16 | 2024-05-16 | Foresee Pharmaceuticals Co., Ltd. | Depot compositions for vesicular monoamine transporter 2 (vmat2) inhbitors |
| TW202521119A (zh) | 2023-08-17 | 2025-06-01 | 美商紐羅克里生物科學有限公司 | 用於投與特定vmat2抑制劑之方法 |
| WO2025038959A1 (en) | 2023-08-17 | 2025-02-20 | Neurocrine Biosciences, Inc. | Methods for the administration of certain vmat2 inhibitors |
| WO2025096823A1 (en) | 2023-11-01 | 2025-05-08 | Neurocrine Biosciences, Inc. | Improvement, maintenance or reduction of decline of motor function associated with huntington disease using valbenazine |
| WO2025188830A1 (en) | 2024-03-06 | 2025-09-12 | Neurocrine Biosciences, Inc. | Methods for the administration of certain vmat2 inhibitors |
Family Cites Families (118)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1068938A (en) | 1910-11-07 | 1913-07-29 | Gustav F Schulze | Vehicle-apron. |
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| JPS5283918A (en) | 1976-01-01 | 1977-07-13 | Wellcome Found | Pharmaceutical composition |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| JPS5777697A (en) | 1980-11-04 | 1982-05-15 | Nippon Zoki Pharmaceut Co Ltd | Physiologically active substance nsq |
| US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| JPS57209225A (en) | 1981-06-18 | 1982-12-22 | Yamasa Shoyu Co Ltd | Antitumor activity intensifier |
| US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
| JPS6028987A (ja) | 1983-07-28 | 1985-02-14 | Chugai Pharmaceut Co Ltd | 新規ジゴキシン誘導体 |
| HU196714B (en) | 1984-10-04 | 1989-01-30 | Monsanto Co | Process for producing non-aqueous composition comprising somatotropin |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| US5612059A (en) | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
| IT1246382B (it) | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5204329A (en) | 1990-06-11 | 1993-04-20 | Du Pont Merck Pharmaceutical Company | Treatment of organ transplantation rejection |
| US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6274552B1 (en) | 1993-03-18 | 2001-08-14 | Cytimmune Sciences, Inc. | Composition and method for delivery of biologically-active factors |
| US5523092A (en) | 1993-04-14 | 1996-06-04 | Emory University | Device for local drug delivery and methods for using the same |
| US5985307A (en) | 1993-04-14 | 1999-11-16 | Emory University | Device and method for non-occlusive localized drug delivery |
| US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6004534A (en) | 1993-07-23 | 1999-12-21 | Massachusetts Institute Of Technology | Targeted polymerized liposomes for improved drug delivery |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5759542A (en) | 1994-08-05 | 1998-06-02 | New England Deaconess Hospital Corporation | Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases |
| US5660854A (en) | 1994-11-28 | 1997-08-26 | Haynes; Duncan H | Drug releasing surgical implant or dressing material |
| US6316652B1 (en) | 1995-06-06 | 2001-11-13 | Kosta Steliou | Drug mitochondrial targeting agents |
| US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
| EP0835101B1 (en) | 1995-06-27 | 2004-06-09 | Takeda Chemical Industries, Ltd. | Method of producing sustained-release preparation |
| TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
| JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
| US6039975A (en) | 1995-10-17 | 2000-03-21 | Hoffman-La Roche Inc. | Colon targeted delivery system |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| TW345603B (en) | 1996-05-29 | 1998-11-21 | Gmundner Fertigteile Gmbh | A noise control device for tracks |
| US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
| ZA977967B (en) | 1996-09-23 | 1999-03-04 | Lilly Co Eli | Combination therapy for treatment of psychoses |
| US6139865A (en) | 1996-10-01 | 2000-10-31 | Eurand America, Inc. | Taste-masked microcapsule compositions and methods of manufacture |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| EP0839525B1 (en) | 1996-10-31 | 2004-08-04 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6131570A (en) | 1998-06-30 | 2000-10-17 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
| EP0946169B1 (en) | 1996-12-20 | 2003-02-26 | Takeda Chemical Industries, Ltd. | Method of producing a sustained-release preparation |
| US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
| US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
| US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
| US6350458B1 (en) | 1998-02-10 | 2002-02-26 | Generex Pharmaceuticals Incorporated | Mixed micellar drug deliver system and method of preparation |
| US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
| US6048736A (en) | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
| KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
| WO2000024399A1 (en) | 1998-10-23 | 2000-05-04 | Sepracor Inc. | Compositions and methods employing r(-) fluoxetine and other active ingredients |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
| EP1313473A2 (en) | 2000-08-30 | 2003-05-28 | Pfizer Products Inc. | Sustained release formulations for growth hormone secretagogues |
| AU2003240818B2 (en) | 2002-05-28 | 2006-05-04 | Bette Pollard | Cardiac glycosides to treat cystic fibrosis and other IL-8 dependent disorders |
| CA2499601A1 (en) | 2002-09-19 | 2004-04-01 | University Of Utah Research Foundation | Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of parkinson's disease |
| US7230097B2 (en) | 2003-03-10 | 2007-06-12 | Lupin Ltd. | Process for preparation of 7-[α-Amino (4-hydroxyphenyl) acetamido]-3-substituted-3-cephem-4-carboxylic acid |
| GB0307259D0 (en) | 2003-03-28 | 2003-05-07 | Glaxo Group Ltd | Process |
| GB2410947B (en) | 2004-02-11 | 2008-09-17 | Cambridge Lab Ltd | Pharmaceutical compounds |
| TWI433682B (zh) | 2004-06-04 | 2014-04-11 | Genentech Inc | Cd20抗體於治療多發性硬化症之用途及用於該用途之物品 |
| EP1799865B1 (en) | 2004-09-30 | 2012-06-06 | Vanda Pharmaceuticals Inc. | Methods for the administration of iloperidone |
| KR20070069182A (ko) | 2004-10-28 | 2007-07-02 | 와이어쓰 | 티게시클린 및 디곡신의 공동투여 |
| WO2006053067A2 (en) | 2004-11-09 | 2006-05-18 | Prestwick Pharmaceuticals, Inc. | Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders |
| AU2006277753B2 (en) | 2005-08-06 | 2011-11-10 | Biovail Laboratories International (Barbados) Srl | 3, hb cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses |
| US20100076087A1 (en) | 2005-10-06 | 2010-03-25 | Auspex Pharmaceuticals, Inc. | Methods of reduction of interpatient variability |
| JP5290185B2 (ja) | 2006-11-08 | 2013-09-18 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 置換３−イソブチル−９，１０−ジメトキシ−１，３，４，６，７，１１ｂ−ヘキサヒドロ−２Ｈ−ピリド［２，１−ａ］イソキノリン−２−オール化合物およびそれに関連する方法 |
| GB0721669D0 (en) | 2007-11-02 | 2007-12-12 | Cambridge Lab Ireland Ltd | Pharmaceutical compounds |
| PT2233474E (pt) | 2008-01-18 | 2015-10-26 | Eisai R&D Man Co Ltd | Derivado de aminodihidrotiazina condensado |
| WO2011019956A2 (en) | 2009-08-12 | 2011-02-17 | Biovail Laboratories International (Barbados) S.R.L. | Pharmaceutical compositions |
| US20110053866A1 (en) | 2008-08-12 | 2011-03-03 | Biovail Laboratories International (Barbados) S.R.L. | Pharmaceutical compositions |
| GB2462611A (en) | 2008-08-12 | 2010-02-17 | Cambridge Lab | Pharmaceutical composition comprising tetrabenazine |
| GB2463451A (en) | 2008-09-08 | 2010-03-17 | Cambridge Lab | 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia |
| GB2463452A (en) | 2008-09-08 | 2010-03-17 | Cambridge Lab | Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof |
| DK2326643T3 (da) | 2008-09-18 | 2013-08-05 | Auspex Pharmaceuticals Inc | Benzoquinolin-inhibitorer fra vesikulær monoamin-transporter 2 |
| US20100096319A1 (en) | 2008-10-17 | 2010-04-22 | General Electric Company | Separator assembly |
| EP3023506B1 (en) * | 2009-04-06 | 2018-03-14 | Vanda Pharmaceuticals Inc. | Method of treatment based on polymorphisms of the kcnq1 gene |
| WO2011153157A2 (en) | 2010-06-01 | 2011-12-08 | Auspex Pharmaceutical, Inc. | Benzoquinolone inhibitors of vmat2 |
| WO2012153341A1 (en) | 2011-05-12 | 2012-11-15 | Arch Pharmalabs Limited | A process for the preparation of iloperidone and pharmaceutically acceptable salts thereof |
| CA2883641C (en) * | 2012-09-18 | 2021-09-14 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| CA2893542C (en) | 2012-12-18 | 2022-07-19 | Vanda Pharmaceuticals Inc. | Use of tasimelteon in the treatment of circadian rhythm disorders |
| HK1219095A1 (zh) | 2013-01-31 | 2017-03-24 | Auspex Pharmaceuticals, Inc. | Vmat2的benzoquinolone抑制剂 |
| WO2015077521A1 (en) * | 2013-11-22 | 2015-05-28 | Auspex Pharmaceuticals, Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| CA2936823A1 (en) | 2014-01-27 | 2015-07-30 | Auspex Pharmaceuticals, Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| AU2015213778B2 (en) | 2014-02-07 | 2020-04-23 | Neurocrine Biosciences, Inc. | Pharmaceutical compositions comprising an antipsychotic drug and a VMAT2 inhibitor and uses thereof |
| EP3102190A4 (en) | 2014-02-07 | 2017-09-06 | Auspex Pharmaceuticals, Inc. | Novel pharmaceutical formulations |
| EP3139925B1 (en) | 2014-05-06 | 2021-12-01 | Neurocrine Biosciences, Inc. | Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders |
| US9714246B2 (en) | 2015-02-06 | 2017-07-25 | Neurocrine Biosciences, Inc. | [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto |
| MX385368B (es) | 2015-03-06 | 2025-03-18 | Auspex Pharmaceuticals Inc | Metodos para el tratamiento de trastornos del movimiento involuntario anormal. |
| CN107921032B (zh) * | 2015-06-23 | 2021-09-24 | 纽罗克里生物科学有限公司 | 用于治疗神经学疾病或病症的vmat2抑制剂 |
| MX381258B (es) | 2015-10-30 | 2025-03-12 | Neurocrine Biosciences Inc | Sales de valbenazina y polimorfos de las mismas. |
| CN121045173A (zh) | 2015-12-23 | 2025-12-02 | 纽罗克里生物科学有限公司 | 制备3-异丁基-9,10-二甲氧基-六氢-1H-吡啶并[2,1-a]异喹啉-2-基2-氨基-3-甲基丁酸酯的盐的方法 |
| TW202515564A (zh) | 2016-12-02 | 2025-04-16 | 美商紐羅克里生物科學有限公司 | 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途 |
| US20200093808A1 (en) | 2017-01-27 | 2020-03-26 | Neurocrine Biosciences, Inc. | Methods for the Administration of Certain VMAT2 Inhibitors |
| WO2018164996A1 (en) | 2017-03-06 | 2018-09-13 | Neurocrine Biosciences, Inc. | Dosing regimen for valbenazine |
| CA3057543A1 (en) | 2017-04-01 | 2018-10-04 | Adeptio Pharmaceuticals Limited | (+)-alpha-dihydrotetrabenazine for use in the treatment a movement disorder |
| CN110691596A (zh) | 2017-04-01 | 2020-01-14 | 阿德普蒂奥制药有限公司 | 药物组合物 |
| JOP20190239A1 (ar) | 2017-04-19 | 2019-10-09 | Neurocrine Biosciences Inc | مركبات مثبطة لـ vmat2 وتركيبات منها |
| WO2018200605A1 (en) | 2017-04-26 | 2018-11-01 | Neurocrine Biosciences, Inc. | Use of valbenazine for treating levodopa-induced dyskinesia |
| EP3426250B1 (en) * | 2017-05-16 | 2022-03-23 | Bow River LLC | Treating a patient with a cyp3a4 substrate drug contraindicated for concomitant administration with a strong cyp3a4 inhibitor |
| US10857144B2 (en) * | 2017-05-16 | 2020-12-08 | Bow River LLC | Methods of treatment |
| EP3684333B1 (en) | 2017-09-21 | 2025-03-05 | Neurocrine Biosciences, Inc. | High dosage valbenazine formulation and compositions, methods, and kits related thereto |
| MY198713A (en) | 2017-10-10 | 2023-09-19 | Neurocrine Biosciences Inc | Methods for the administration of certain vmat2 inhibitors |
| KR20250070134A (ko) | 2017-10-10 | 2025-05-20 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| RU2020117345A (ru) | 2017-11-22 | 2021-12-23 | Ассиа Кемикал Индастриз Лтд | Твердая форма валбеназина |
| JOP20200298A1 (ar) | 2018-06-14 | 2020-11-22 | Neurocrine Biosciences Inc | مركبات مثبطة لـ vmat2 وتركيبات وطرق تتعلق بها |
| MX2021001017A (es) | 2018-08-15 | 2021-04-19 | Neurocrine Biosciences Inc | Metodos para la administracion de ciertos inhibidores de transportador vesicular de monoamina de proteinas transportadoras-2 (vmat2). |
| JP2022531696A (ja) | 2019-05-09 | 2022-07-08 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 特定のｖｍａｔ２阻害剤を投与するための方法 |
| US10689380B1 (en) | 2019-07-30 | 2020-06-23 | Farmhispania S.A. | Crystalline forms of valbenazine ditosylate |
| US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
-
2017
- 2017-10-10 US US16/481,037 patent/US20200093808A1/en not_active Abandoned
- 2017-10-10 WO PCT/US2017/055965 patent/WO2018140095A2/en not_active Ceased
- 2017-10-10 KR KR1020237041798A patent/KR20230170136A/ko not_active Ceased
- 2017-10-10 EA EA202090676A patent/EA202090676A1/ru unknown
- 2017-10-10 KR KR1020257002857A patent/KR20250022883A/ko active Pending
- 2017-10-10 KR KR1020207012774A patent/KR20200066662A/ko not_active Ceased
- 2017-10-10 MY MYPI2020001816A patent/MY202219A/en unknown
- 2017-10-10 KR KR1020197024657A patent/KR20190108149A/ko not_active Ceased
- 2017-10-10 KR KR1020257002858A patent/KR20250020723A/ko active Pending
- 2017-10-10 MX MX2020003462A patent/MX2020003462A/es unknown
- 2017-10-10 MY MYPI2019004296A patent/MY199695A/en unknown
- 2017-10-10 CN CN201780088730.3A patent/CN110740731A/zh active Pending
- 2017-10-10 CA CA3051834A patent/CA3051834C/en active Active
- 2017-10-10 KR KR1020197024655A patent/KR20190108147A/ko not_active Ceased
- 2017-10-10 AU AU2017395703A patent/AU2017395703B2/en active Active
- 2017-10-10 WO PCT/US2017/055931 patent/WO2018140094A1/en not_active Ceased
- 2017-10-10 EA EA201991782A patent/EA201991782A1/ru unknown
- 2017-10-10 CN CN201780088766.1A patent/CN110740732A/zh active Pending
- 2017-10-10 SG SG11201906891RA patent/SG11201906891RA/en unknown
- 2017-10-10 JP JP2019540650A patent/JP7107950B2/ja active Active
- 2017-10-10 CN CN201780088736.0A patent/CN110709071A/zh active Pending
- 2017-10-10 CA CA3051830A patent/CA3051830A1/en active Pending
- 2017-10-10 EA EA201991786A patent/EA201991786A1/ru unknown
- 2017-10-10 CA CA3051832A patent/CA3051832C/en active Active
- 2017-10-10 US US16/481,033 patent/US10874648B2/en active Active
- 2017-10-10 MX MX2019008855A patent/MX394417B/es unknown
- 2017-10-10 WO PCT/US2017/055980 patent/WO2018140096A1/en not_active Ceased
- 2017-10-10 CA CA3078719A patent/CA3078719A1/en active Pending
- 2017-10-10 AU AU2017395701A patent/AU2017395701B2/en active Active
- 2017-10-10 KR KR1020257002855A patent/KR20250020722A/ko active Pending
- 2017-10-10 EA EA201991780A patent/EA201991780A1/ru unknown
- 2017-10-10 JP JP2019540570A patent/JP7199361B2/ja active Active
- 2017-10-10 PH PH1/2022/553251A patent/PH12022553251A1/en unknown
- 2017-10-10 MY MYPI2019004292A patent/MY195934A/en unknown
- 2017-10-10 SG SG11201906885TA patent/SG11201906885TA/en unknown
- 2017-10-10 KR KR1020197024656A patent/KR20190108148A/ko not_active Ceased
- 2017-10-10 MX MX2019008854A patent/MX394418B/es unknown
- 2017-10-10 AU AU2017395704A patent/AU2017395704B8/en active Active
- 2017-10-10 CN CN201780097535.7A patent/CN111655034A/zh active Pending
- 2017-10-10 JP JP2020520311A patent/JP7090151B2/ja active Active
- 2017-10-10 KR KR1020207030652A patent/KR20200126430A/ko not_active Ceased
- 2017-10-10 KR KR1020237041797A patent/KR20230170135A/ko not_active Ceased
- 2017-10-10 WO PCT/US2017/055907 patent/WO2018140093A1/en not_active Ceased
- 2017-10-10 CN CN201780088897.XA patent/CN110769826A/zh active Pending
- 2017-10-10 JP JP2019540568A patent/JP7199360B2/ja active Active
- 2017-10-10 MY MYPI2019004293A patent/MY191077A/en unknown
- 2017-10-10 AU AU2017395700A patent/AU2017395700B2/en active Active
- 2017-10-10 SG SG11201906883SA patent/SG11201906883SA/en unknown
- 2017-10-10 KR KR1020237041673A patent/KR20230169457A/ko not_active Ceased
- 2017-10-10 KR KR1020257017150A patent/KR20250078629A/ko active Pending
- 2017-10-10 JP JP2019540557A patent/JP7199359B2/ja active Active
- 2017-10-10 CA CA3051829A patent/CA3051829A1/en active Pending
- 2017-10-10 KR KR1020197024654A patent/KR20190108146A/ko not_active Ceased
- 2017-10-10 MY MYPI2019004294A patent/MY203491A/en unknown
- 2017-10-10 US US16/481,029 patent/US20190381016A1/en not_active Abandoned
- 2017-10-10 MX MX2019008853A patent/MX394415B/es unknown
- 2017-10-10 WO PCT/US2017/055877 patent/WO2018140092A1/en not_active Ceased
- 2017-10-10 EA EA201991784A patent/EA201991784A1/ru unknown
- 2017-10-10 MX MX2019008868A patent/MX393077B/es unknown
- 2017-10-10 KR KR1020237007871A patent/KR20230038601A/ko not_active Ceased
- 2017-10-10 CN CN202310682815.1A patent/CN116712434A/zh active Pending
- 2017-10-10 AU AU2017395702A patent/AU2017395702B2/en active Active
-
2019
- 2019-07-25 MX MX2022007141A patent/MX2022007141A/es unknown
- 2019-07-26 PH PH12019501744A patent/PH12019501744A1/en unknown
- 2019-07-26 PH PH12019501740A patent/PH12019501740A1/en unknown
- 2019-07-26 PH PH12019501734A patent/PH12019501734A1/en unknown
- 2019-07-26 PH PH12019501732A patent/PH12019501732A1/en unknown
-
2020
- 2020-04-08 PH PH12020550238A patent/PH12020550238A1/en unknown
- 2020-05-08 US US16/870,423 patent/US10952997B2/en active Active
- 2020-05-08 US US16/870,706 patent/US10857137B2/en active Active
- 2020-05-08 US US16/870,572 patent/US11040029B2/en active Active
- 2020-10-17 US US17/073,304 patent/US10912771B1/en active Active
- 2020-10-26 US US17/080,343 patent/US11439629B2/en active Active
- 2020-12-17 US US17/125,190 patent/US20210169862A1/en not_active Abandoned
-
2022
- 2022-01-24 JP JP2022008580A patent/JP2022040408A/ja not_active Withdrawn
- 2022-05-12 AU AU2022203201A patent/AU2022203201B2/en active Active
- 2022-05-17 AU AU2022203327A patent/AU2022203327A1/en not_active Abandoned
- 2022-07-14 JP JP2022113075A patent/JP2022137219A/ja not_active Withdrawn
- 2022-10-04 JP JP2022160177A patent/JP2022174343A/ja not_active Withdrawn
- 2022-10-05 JP JP2022160831A patent/JP2022174344A/ja not_active Withdrawn
- 2022-10-05 JP JP2022160833A patent/JP2022174345A/ja not_active Withdrawn
-
2023
- 2023-09-15 JP JP2023149999A patent/JP2023161033A/ja active Pending
-
2024
- 2024-06-06 JP JP2024092148A patent/JP2024107167A/ja active Pending
- 2024-06-06 JP JP2024092152A patent/JP2024107168A/ja active Pending
- 2024-06-06 JP JP2024092155A patent/JP2024107169A/ja active Pending
- 2024-06-07 JP JP2024093040A patent/JP2024113134A/ja active Pending
-
2025
- 2025-07-29 JP JP2025126262A patent/JP2025146959A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020003462A (es) | Metodos para la administracion de ciertos inhibidores del transportador vesicular de monoamina 2 (vmat2). | |
| MX2020003421A (es) | Metodos para la administracion de ciertos inhibidores del transportador vesicular de monoamina 2 (vmat2). | |
| PH12021550302A1 (en) | Methods for the administration of certain vmat2 inhibitors | |
| ECSP20025899A (es) | Compuestos útiles para inhibir a cdk7 | |
| AR107864A1 (es) | ÁCIDO 7a,11b-DIHIDROXI-6a-ETIL-5b-COLAN-24-OICO Y COMPOSICIONES FARMACÉUTICAS | |
| AR093705A1 (es) | Depsipeptido y sus usos | |
| MX2017009449A (es) | Inhibidor jak. | |
| CL2013002417A1 (es) | Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas. | |
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| SA519410865B1 (ar) | مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه | |
| DOP2016000254A (es) | Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso. | |
| DOP2022000076A (es) | Inhibidores del factor d del complemento para administración oral | |
| MX2019008302A (es) | Inhibidores biciclicos de histona desacetilasa. | |
| MX2021014680A (es) | Derivado de benzotriazol. | |
| ECSP22036455A (es) | Inhibidores del factor d del complemento para administraci?n oral | |
| AR128051A1 (es) | Inhibidores de parp1 | |
| EA202190252A1 (ru) | Способы введения определенных ингибиторов vmat2 | |
| BR112018073556A2 (pt) | medicamento e composição farmacêutica para a prevenção ou o tratamento da neuralgia trigeminal, método para prevenir ou tratar neuralgia trigeminal em um indivíduo, e, uso de um composto de carbamato . |